Vendor neutral archive (VNA) is an image management solution that allows medical images and associated reports to be stored, queried, and retrieved by any healthcare application from multiple sources and modalities. Traditionally, healthcare organizations have had to manage multiple PACS systems to store and access radiology images which led to increased costs and technological complexities. A VNA provides a central repository that consolidates imaging data from all departments, sources, and specialties in a single archive. This facilitates interoperability, universal access, and optimized care collaboration.
Market Dynamics:
The growth of the vendor neutral archive (VNA) market is driven by factors such as rising imaging volumes due to increasing prevalence of chronic diseases, growing preferences for centralized medical imaging storage systems, and need to improve data sharing and enhance patient care coordination across various care delivery settings. However, high costs associated with the deployment and maintenance of VNAs as well as lack of expertise especially in small healthcare facilities limit their widespread adoption. Meanwhile, growing telehealth practices, technological advancements to enable artificial intelligence integration, and predictive analytics present lucrative opportunities for vendors.
Key features of the study:
- This report provides an in-depth analysis of the global vendor neutral archive (VNA) market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global vendor neutral archive (VNA) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Johnson & Johnson Private Limited, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Baxter, Bayer AG, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin , Allergan, AbbVie Inc., Abbott, Bausch Health Companies Inc. , Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, and AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global vendor neutral archive (VNA) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vendor neutral archive (VNA) market
Detailed Segmentation:
- Global Vendor Neutral Archive (VNA) Market, By Deployment Model
- On-Premise VNA
- Cloud-Based VNA
- Global Vendor Neutral Archive (VNA) Market, By Vendor Type
- Independent Software Vendors (ISVs)
- PACS Vendors
- Infrastructure Vendors
- Global Vendor Neutral Archive (VNA) Market, By Imaging Type
- Radiology VNAs
- Cardiology VNAs
- Pathology VNAs
- Global Vendor Neutral Archive (VNA) Market, By End-User
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Care Centers
- Research and Academic Institutes
- Global Vendor Neutral Archive (VNA) Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Global Vendor Neutral Archive (VNA) Market, Key Players
- Johnson & Johnson Private Limited
- Merck & Co., Inc.
- F.Hoffmann-La Roche Ltd.
- Baxter
- Bayer AG
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Allergan
- AbbVie Inc.
- Abbott
- Bausch Health Companies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- AstraZeneca
